Stryker Corp (SYK) is a renowned Fortune 500 medical technologies firm based in Kalamazoo, Michigan, USA. Since its inception in 1941 by Dr. Homer Stryker, the company has been committed to "making healthcare better". It has emerged as a global leader in the medical technology industry and provides innovative products and services in the areas of Orthopaedics, Medical and Surgical, and Neurotechnology and Spine.
Stryker's unique product portfolio is designed to help medical professionals enhance their performance, reduce healthcare costs, and most importantly, improve the lives of their patients. The company’s orthopaedics line includes joint replacements and trauma, craniomaxillofacial & thoracic products. Their medical and surgical equipment consists of surgical navigation systems, endoscopic systems, patient handling equipment, and more. Stryker's Neurotechnology and spine products include neurosurgical, neurovascular and spinal devices.
A key focus of Stryker Corp is its dedication to technological innovation, and it consistently reinvests in R&D to develop advanced medical solutions. The company’s commitment to growth is also evident in its strategic acquisitions and partnerships, as it routinely seeks to expand its reach and capabilities. Examples include their acquisition of Wright Medical Group, a global orthopaedic medical device company, and the collaboration with Microsoft to use HoloLens technology in operating rooms.
Stryker Corp’s mission and values are deeply ingrained in its operations. The company stands for integrity and puts great emphasis on its culture of accountability. The firm also takes pride in offering a diverse and inclusive work environment. They are dedicated to sustainability and believe in a "green" approach to business, which includes efforts to reduce their carbon footprint.
With a workforce of over 33,000 employees worldwide, the company generated a revenue of $14.4 billion as of 2020. Despite facing challenges amidst the COVID-19 pandemic, Stryker showcased commendable resilience and adaptability. The company continues to leverage its robust business model, a well-diversified product portfolio, and technological advancements to drive growth in the post-pandemic era.
In conclusion, Stryker Corp is a testament to the power of innovation in the medical sciences field. Their approach to healthcare solutions continues to contribute significantly to the betterment of patient health and the evolution of the global medical technology industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Engineers Gate Manager LP significantly reduced its stake in Stryker Corporation by selling 27,714 shares, cutting its holdings by 96.1%. Despite this, institutional investors and hedge funds still own a substantial 77.09% of SYK. Stryker, trading near its 12-month low, maintains a "Moderate Buy" consensus from analysts with an average price target of $374.42, driven by strong earnings and dividend performance.
Stryker (SYK) recently unveiled new Foot & Ankle technologies, including the Prophecy Surgical Planning for its Incompass Total Ankle System, which integrates preoperative data into product development and surgical workflows. This innovation is expected to reinforce Stryker's strategy of driving growth through data-guided implants and complex procedures, despite current challenges like manufacturing disruptions and legal scrutiny. Analysts project significant revenue and earnings growth for Stryker by 2029, with some estimates suggesting a potential 35% upside to its current stock price.
Envestnet Asset Management Inc. increased its holdings in Stryker Corporation by 12.2% in the second quarter, purchasing 70,634 additional shares to own a total of 650,461 shares valued at approximately $204.8 million. Institutional investors now hold 77.09% of Stryker's stock, while company insiders have sold shares worth about $118.2 million in the last 90 days. Analysts maintain a "Moderate Buy" consensus rating for Stryker with an average price target of $374.42, following strong quarterly results where earnings and revenue exceeded expectations.
Abbott Laboratories recently announced a partnership with Berry Street, integrating its Lingo glucose monitor with virtual nutrition coaching, alongside the expansion of its Volt Pulsed Field Ablation System for cardiac procedures. This collaboration, especially with Lingo, aims to extend glucose tracking beyond traditional diabetes care, influencing Abbott's long-term investment narrative by pushing into everyday health use cases, though near-term earnings risks persist due to legal and regulatory issues in its Nutrition arm. While the partnership supports Abbott's operational goals and potential revenue growth, its impact on the company's financial forecasts and overall fair value remains a subject of varied analyst opinions.
Pomerantz LLP is investigating potential claims on behalf of investors of Stryker Corp. (NYSE: SYK) following a significant drop in its stock price. The investigation concerns whether Stryker engaged in securities fraud or unlawful business practices after the CEO disclosed that a manufacturing problem affecting inventory supply in its peripheral vascular business remained unresolved, contrary to previous expectations. Stryker's stock fell 8.81% on September 8, 2026, after this announcement.
QRG Capital Management Inc. has reduced its stake in Stryker Corporation (NYSE:SYK) by 11.2%, selling 7,952 shares but still retaining 63,017 shares valued at $19.84 million. This move comes as other institutional investors have adjusted their positions, and company insiders have sold a significant number of shares. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $374.42 for Stryker, which recently reported strong quarterly earnings and revenue growth.
Mercury Systems EVP Stuart Kupinsky sold 1,000 shares of the company's stock for $86,520 on September 21st, reducing his holdings by 1.61%. This sale was part of a pre-arranged trading plan, and he has made several other sales since mid-August. The company's shares are currently trading below key moving averages and its one-year high, despite exceeding revenue forecasts in its last quarterly earnings.